Technology
Health
Biotechnology

Diffusion Pharmaceuticals

$4.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-5.58%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell DFFN and other stocks, options, ETFs, and crypto commission-free!

About

Diffusion Pharmaceuticals Inc. Common Stock, also called Diffusion Pharmaceuticals, is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. Read More The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Employees
10
Headquarters
Charlottesville, Virginia
Founded
2001
Market Cap
14.86M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
167.38K
High Today
$4.47
Low Today
$4.23
Open Price
$4.43
Volume
27.57K
52 Week High
$11.00
52 Week Low
$1.83

Collections

Technology
Health
Biotechnology
Medical
2018 IPO
US
North America

News

Yahoo FinanceMay 9

Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

Enrollment in Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke to begin in Q3 CHARLOTTESVILLE, Va., May 09, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for the three months ended March 31, 2019 and provided a business update. During the first...

194
Markets InsiderMay 2

6 Top Gainers In Pharma Sector (DFFN, QTNT, ORGO...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Diffusion Pharmaceuticals Inc. (DFFN) Diffusion Pharma is a clinical stage biotechnology company developing treatments for life-threatening medical conditions. Gained 91.56% to close Thursday's (May 2) trading at $5.90. News: No news Clinical Trials: The Company's lead drug candidate is Trans Sodium Crocinate. A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer,...

575

Earnings

-$0.90
-$0.62
-$0.34
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.90 per share
Actual
-$0.81 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.